293 related articles for article (PubMed ID: 22047791)
1. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Levy I; Horvath A; Azevedo M; de Alexandre RB; Stratakis CA
Curr Opin Pharmacol; 2011 Dec; 11(6):689-97. PubMed ID: 22047791
[TBL] [Abstract][Full Text] [Related]
2. PDE inhibitors: a new approach to treat metabolic syndrome?
Lugnier C
Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
Manganiello V
Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
[No Abstract] [Full Text] [Related]
4. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
5. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
Kass DA
Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
[No Abstract] [Full Text] [Related]
6. Phosphodiesterases and regulation of female reproductive function.
Conti M
Curr Opin Pharmacol; 2011 Dec; 11(6):665-9. PubMed ID: 22019564
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
[TBL] [Abstract][Full Text] [Related]
8. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
9. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
10. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
11. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
12. Cyclic GMP and regulation of cyclic nucleotide hydrolysis.
Sonnenburg WK; Beavo JA
Adv Pharmacol; 1994; 26():87-114. PubMed ID: 8038108
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide phosphodiesterase assay technology.
MacKenzie SJ; Hastings SF; Wells C
Curr Protoc Pharmacol; 2010 Jun; Chapter 3():Unit 3.12. PubMed ID: 22294369
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
15. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
16. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
19. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
20. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
Raeburn D; Advenier C
Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]